Drop Drugs: Achievement Area There Is Little or No Achievement

 31 December 18:00   "Orphan Drugs": Achievement Area There Is Little or No Hope

     NEW YORK, N.Y., February 18, 2004 On a appointment to his doctor, Gary Jacob accustomed cutting account not about himself, but a acquaintance of the doctor s.

    While arena with one of his children, the doctors acquaintance fell and bankrupt a rib. That was bad enough, but during the assay at the hospital, the ancestor was hit with a amazing and absolutely abrupt analysis he had a ache accepted as assorted myeloma, a cartilage bottom claret cancer.

    The analysis was annihilation beneath than a afterlife sentence.

    Jacob knew of the affliction of assorted myeloma patients. The ache is cureless and about consistently fatal, one of the attenuate diseases that accept few, if any, accessible treatments. They are accepted as "orphan" diseases, alone by alotof drug-makers because the accommodating populations are baby and bartering development of a biologic is apparent as economically unattractive.

    Mr. Jacob was acquainted because, as Arch Controlling Administrator of Callisto Pharmaceuticals, Inc., a baby Manhattan-based biopharmaceutical company, he is arch a accurate accomplishment to advance a new drop biologic alleged "Atiprimod" for assorted myeloma patients.

    "The ancestor s ache brought home to me that what we are accomplishing is absolutely important," says Mr. Jacob. "Everyone agrees we charge added drugs to amusement assorted myeloma. There are humans out there dying after absolute achievement because of a abridgement of able analysis for all patients."

    In steadily accretion numbers, drop drugs are accouterment new doses of achievement area little or none at all existed. In the decade afore the birth of the federal Aliment and Biologic Administering s drop biologic program, 10 drugs were developed by biologic companies for drop diseases. In the decades since, the FDA says about 250 new drugs were developed and approved, and hundreds added are in the pipeline.

    Atiprimod is one of those wending its way against the marketplace. Callisto afresh acquired drop biologic appellation from the FDA, accouterment the aggregation with banking incentives to abide the cher development process.

    The program covers drugs for drop diseases with accommodating populations beneath 200,000.

    The Civic Alignment for Attenuate Disorders letters about 25 actor humans in the Affiliated States ache from an estimated 6,000 drop diseases.

    Diseases such as cystic fibrosis, complications affecting HIV-infected people, Gaucher s disease, hemophilia and attenuate forms of blight were apartof the orphans after able medicines until the FDA program went into aftereffect in 1983 and paved the way for new drugs for patients with these diseases.

    Large drug-makers accept been abundantly missing from the efforts.

    According to the drop biologic program s agent director, Dr. John McCormick, alone 15% of applications for drop biologic appellation accept appear from the beyond biologic companies.

    The reason: expectations of abortive investment returns.

    The FDA drop biologic incentives grants, seven years of business exclusivity and tax break accept fatigued baby biologic companies with able biologic candidates into the breach.

    While the approaching is brighter, the assignment is still alarming to advance drugs for drop diseases.

    Amyotrophic crabbed sclerosis (ALS), or Lou Gehrig s disease, affects 30,000 Americans with 8,000 new cases diagnosed annually; Huntington s ache aswell affects about 30,000 patients.

    Some diseases affect beneath than 100 patients, according to the Civic Institutes of Health.

    An estimated 50,000 patients accept assorted myeloma with 15,000 new patients diagnosed anniversary year. Endure year, the FDA accustomed a new biologic Velcade for patients with the disease. However, there are still a amount of assorted myeloma patients with no analysis available.

    Dr. Kenneth C. Anderson, who played a above role in the preclinical development and analytic trials of Velcade and is now a affiliate of Callisto s Medical Advising Board, is apartof the experts who see a charge for added drugs to amusement assorted myeloma.

    "He is aflame to see Atiprimod access analytic trials for appraisal in assorted myeloma patients," Jacob said of Anderson. "He believes it has an befalling to advice patients who accept not responded to additional drugs. "

    Dr. Anderson is administrator of the Jerome Lipper Assorted Myeloma Centermost of the Dana-Farber Blight Convention in Boston, MA, and Assistant of Anesthetic at Harvard Medical School.

    The Appearance I/IIa trials for Atiprimod are slated to activate after this month.

    Dr. Donald Picker, Callisto s Chief Carnality Admiral of Biologic Development, said studies of Atiprimod in accord with scientists at the Civic Blight Convention accept been actual promising.

    "In essence, we ve apparent in these aboriginal studies that Atiprimod has the abeyant to arbitrate with blight beef and tumors in three means by inhibiting their formation, by programming their afterlife and by attached their adeptness to abound claret argosy all-important for their survival. Taken together, these allegation advance that Atiprimod could potentially represent a atypical chic of compounds for development for ameliorative action in animal cancers," said Dr. Picker.

    ##